| Autor: |
Anxin, Wang, Xuewei, Xie, Xue, Tian, S Claiborne, Johnston, Hao, Li, Philip M, Bath, Yingting, Zuo, Jing, Jing, Jinxi, Lin, Yilong, Wang, Xingquan, Zhao, Zixiao, Li, Yong, Jiang, Liping, Liu, Xia, Meng, Yongjun, Wang |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Annals of internal medicine. 175(11) |
| ISSN: |
1539-3704 |
| Popis: |
Evidence on the risk-benefit ratio of dual antiplatelet therapies among patients with stroke and impaired renal function is limited and inconsistent.To investigate the effect of renal function on the efficacy and safety of ticagrelor-aspirin versus clopidogrel-aspirin treatment.Post hoc analysis of a multicenter, randomized, double-blind, placebo-controlled trial. (ClinicalTrials.gov: NCT04078737).202 centers in China.Ticagrelor-aspirin and clopidogrel-aspirin.Renal function was evaluated by estimated glomerular filtration rate (eGFR) levels. The primary efficacy and safety outcomes were recurrent stroke and severe or moderate bleeding within 90 days, respectively.Among 6378 patients, 4050 (63.5%) had normal (eGFR ≥90 mL/min/1.73 mRenal function was only evaluated by using eGFR, and the proportion of patients with severely decreased renal function was low.Patients with normal, rather than impaired, renal function received greater benefit from ticagrelor-aspirin versus clopidogrel-aspirin.Ministry of Science and Technology of the People's Republic of China. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
